Avandia Should Stay On Market With Warnings, Committee Says

FDA's Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees are calling for strengthened warnings for GlaxoSmithKline's type 2 diabetes drug Avandia due to cardiovascular safety concerns, but not its withdrawal from the market